×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CPIX – cumberland pharmaceuticals inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CPIX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/18
03:07 am
cpix
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/10
07:47 am
cpix
Cumberland Pharmaceuticals Third Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023) [Yahoo! Finance]
High
Report
Cumberland Pharmaceuticals Third Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023) [Yahoo! Finance]
11/10
02:03 am
cpix
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
High
Report
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/8
06:06 pm
cpix
Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ... [Yahoo! Finance]
Low
Report
Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ... [Yahoo! Finance]
11/7
04:05 pm
cpix
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
Low
Report
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
11/6
05:31 pm
cpix
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY [Yahoo! Finance]
High
Report
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY [Yahoo! Finance]
11/6
05:21 pm
cpix
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Neutral
Report
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
11/5
04:05 pm
cpix
New Study Compares Caldolor® (ibuprofen injection) to ketorolac
Low
Report
New Study Compares Caldolor® (ibuprofen injection) to ketorolac
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
09:33 am
cpix
Form 8-K CUMBERLAND PHARMACEUTICA For: Nov 06
Low
Report
Form 8-K CUMBERLAND PHARMACEUTICA For: Nov 06
11/8
05:05 pm
cpix
Form 10-Q CUMBERLAND PHARMACEUTICA For: Sep 30
Low
Report
Form 10-Q CUMBERLAND PHARMACEUTICA For: Sep 30
11/7
05:13 pm
cpix
Form 8-K CUMBERLAND PHARMACEUTICA For: Nov 07
Medium
Report
Form 8-K CUMBERLAND PHARMACEUTICA For: Nov 07
11/6
05:12 pm
cpix
Form 8-K CUMBERLAND PHARMACEUTICA For: Nov 06
Neutral
Report
Form 8-K CUMBERLAND PHARMACEUTICA For: Nov 06
11/5
04:40 pm
cpix
Form 4 CUMBERLAND PHARMACEUTICA For: Oct 01 Filed by: Young Caroline
Low
Report
Form 4 CUMBERLAND PHARMACEUTICA For: Oct 01 Filed by: Young Caroline
11/5
04:40 pm
cpix
Form 4 CUMBERLAND PHARMACEUTICA For: Oct 01 Filed by: Jones James
Low
Report
Form 4 CUMBERLAND PHARMACEUTICA For: Oct 01 Filed by: Jones James
11/5
04:39 pm
cpix
Form 4 CUMBERLAND PHARMACEUTICA For: Oct 01 Filed by: KAZIMI A J
Low
Report
Form 4 CUMBERLAND PHARMACEUTICA For: Oct 01 Filed by: KAZIMI A J
11/5
04:38 pm
cpix
Form 4 CUMBERLAND PHARMACEUTICA For: Oct 01 Filed by: Krogulski Kenneth
Low
Report
Form 4 CUMBERLAND PHARMACEUTICA For: Oct 01 Filed by: Krogulski Kenneth
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/10
Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating.
17.0%
3/4 Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2019 Financial Results 15.9%
5/7 Cumberland Pharmaceuticals To Announce First Quarter 2019 Financial Results 13.3%
12/2 Cumberland Pharmaceuticals Receives FDA Approval for RediTrex™ Product Line 9.3%
4/7 To Help Prepare for the COVID-19 Patient Surge Cumberland Pharmaceuticals Expands Availability of Vaprisol® to Treat Hyponatremia in Critical Care Units 8.1%
5/15 Form 10-Q CUMBERLAND PHARMACEUTICA For: Mar 31 7.1%
11/19 Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) had its price target lowered by analysts at B. Riley from $12.25 to $9.00. They now have a "buy" rating on the stock. 5.2%
9/27 Form 8-K CUMBERLAND PHARMACEUTICA For: Sep 27 5.1%
5/17 Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $7.00 price target on the stock. 4.6%
5/14 Q1/2019 3/31/2019 EPS 0.110 ZacksConsensus -0.110 ActVsEst 0.220 - Beat 4.1%
3/4 Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2019 Financial Results 15.9%
5/7 Cumberland Pharmaceuticals To Announce First Quarter 2019 Financial Results 13.3%
12/2 Cumberland Pharmaceuticals Receives FDA Approval for RediTrex™ Product Line 9.3%
4/7 To Help Prepare for the COVID-19 Patient Surge Cumberland Pharmaceuticals Expands Availability of Vaprisol® to Treat Hyponatremia in Critical Care Units 8.1%
5/15 Form 10-Q CUMBERLAND PHARMACEUTICA For: Mar 31 7.1%
11/19 Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) had its price target lowered by analysts at B. Riley from $12.25 to $9.00. They now have a "buy" rating on the stock. 5.2%
9/27 Form 8-K CUMBERLAND PHARMACEUTICA For: Sep 27 5.1%
5/17 Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $7.00 price target on the stock. 4.6%
5/14 Q1/2019 3/31/2019 EPS 0.110 ZacksConsensus -0.110 ActVsEst 0.220 - Beat 4.1%
TOP News Decliners
11/12
Q3/2019 9/30/2019 EPS 0.010 ZacksConsensus 0.090 ActVsEst (0.080) - Miss
-13.6%
9/10 Form 8-K CUMBERLAND PHARMACEUTICA For: Sep 10 -6.8%
8/30 Form 4 CUMBERLAND PHARMACEUTICA For: Aug 23 Filed by: Bernard Gordon R -6.7%
12/3 Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) had its price target raised by analysts at B. Riley from $9.00 to $9.75. They now have a "buy" rating on the stock. -5.0%
1/7 Cumberland Pharmaceuticals Announces The National Launch Of A New Caldolor Ready-To-Use Product -4.1%
5/14 Form 8-K CUMBERLAND PHARMACEUTICA For: May 14 -4.1%
8/16 Form 4 CUMBERLAND PHARMACEUTICA For: Aug 01 Filed by: Bernard Gordon R -3.9%
3/20 Form 10-K CUMBERLAND PHARMACEUTICA For: Dec 31 -3.8%
9/24 Cumberland Pharmaceuticals Announces FDA Orphan Drug Grant Award For New Phase II Clinical Program -3.6%
1/3 Form 8-K CUMBERLAND PHARMACEUTICA For: Jan 03 -3.6%
9/10 Form 8-K CUMBERLAND PHARMACEUTICA For: Sep 10 -6.8%
8/30 Form 4 CUMBERLAND PHARMACEUTICA For: Aug 23 Filed by: Bernard Gordon R -6.7%
12/3 Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) had its price target raised by analysts at B. Riley from $9.00 to $9.75. They now have a "buy" rating on the stock. -5.0%
1/7 Cumberland Pharmaceuticals Announces The National Launch Of A New Caldolor Ready-To-Use Product -4.1%
5/14 Form 8-K CUMBERLAND PHARMACEUTICA For: May 14 -4.1%
8/16 Form 4 CUMBERLAND PHARMACEUTICA For: Aug 01 Filed by: Bernard Gordon R -3.9%
3/20 Form 10-K CUMBERLAND PHARMACEUTICA For: Dec 31 -3.8%
9/24 Cumberland Pharmaceuticals Announces FDA Orphan Drug Grant Award For New Phase II Clinical Program -3.6%
1/3 Form 8-K CUMBERLAND PHARMACEUTICA For: Jan 03 -3.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: